Advances in Parametric Mapping With CMR Imaging

Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia.
JACC. Cardiovascular imaging (Impact Factor: 7.19). 07/2013; 6(7):806-822. DOI: 10.1016/j.jcmg.2013.05.005
Source: PubMed


Cardiac magnetic resonance imaging (CMR) is well established and considered the gold standard for assessing myocardial volumes and function, and for quantifying myocardial fibrosis in both ischemic and nonischemic heart disease. Recent developments in CMR imaging techniques are enabling clinically-feasible rapid parametric mapping of myocardial perfusion and magnetic relaxation properties (T1, T2, and T2* relaxation times) that are further expanding the range of unique tissue parameters that can be assessed using CMR. To generate a parametric map of perfusion or relaxation times, multiple images of the same region of the myocardium are acquired with different sensitivity to the parameter of interest, and the signal intensities of these images are fit to a model which describes the underlying physiology or relaxation parameters. The parametric map is an image of the fitted perfusion parameters or relaxation times. Parametric mapping requires acquisition of multiple images typically within a breath-hold and thus requires specialized rapid acquisition techniques. Quantitative perfusion imaging techniques can more accurately determine the extent of myocardial ischemia in coronary artery disease and provide the opportunity to evaluate microvascular disease with CMR. T1 mapping techniques performed both with and without contrast are enabling quantification of diffuse myocardial fibrosis and myocardial infiltration. Myocardial edema and inflammation can be evaluated using T2 mapping techniques. T2* mapping provides an assessment of myocardial iron-overload and myocardial hemorrhage. There is a growing body of evidence for the clinical utility of quantitative assessment of perfusion and relaxation times, although current techniques still have some important limitations. This article will review the current imaging technologies for parametric mapping, emerging applications, current limitations, and potential of CMR parametric mapping of the myocardium. The specific focus will be the assessment and quantification of myocardial perfusion and magnetic relaxation times.

14 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Positron emission tomography-magnetic resonance imaging (PET/MRI) is emerging as a novel diagnostic modality with exciting potential for a role in multiple cardiovascular applications. The combination of the high sensitivity of PET tracers with the excellent spatial resolution and tissue characterization of cardiac MRI will provide complementary information in a variety of cardiac pathologies. While initial efforts have focused on the combination of MRI and PET for assessment of coronary artery disease, cardiomyopathy, viability, and inflammation, this new technology holds enormous potential for molecular cardiovascular imaging. This article will review the development of PET/MRI, review the current research, and discuss potential future applications.
    Journal of Nuclear Cardiology 08/2013; 20(6). DOI:10.1007/s12350-013-9780-5 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: -LGE by CMR is a predictor of adverse cardiovascular outcomes in non-ischemic cardiomyopathy (NICM) patients. However, these findings are limited by single center studies, small sample sizes, and low event rates. We performed a meta-analysis to evaluate the prognostic role of late-gadolinium enhancement by cardiac magnetic resonance (LGE-CMR) imaging in NICM patients. -PubMed, Cochrane CENTRAL and EMBASE were searched for studies looking at the prognostic value of LGE-CMR in NICM patients. The primary end-points included all-cause mortality, heart failure hospitalization (HFH), and a composite end point of sudden cardiac death (SCD) or aborted SCD. Pooling of odds ratios (OR) was performed using a random-effect model and annualized event rates (AER) were assessed. Data was included from 9 studies with a total of 1,488 patients and a mean follow-up of 30 months. Patients had a mean age of 52 years, 67% were male and the average LVEF was 37% on CMR. LGE was present in 38% of patients. Patients with LGE had increased overall mortality (OR 3.27, p<0.00001), HFH (OR 2.91, p=0.02), and SCD/aborted SCD (OR 5.32, p<0.00001) when compared with those without LGE. The AERs for mortality were 4.7% for LGE+ subjects vs. 1.7% for LGE- subjects (p=0.01), 5.03% vs. 1.8% for HFH (p=0.002), and 6.0% vs. 1.2% for SCD/aborted SCD (p<0.001). -LGE in NICM patients is associated with increased risk of all-cause mortality, HFH, and SCD. Detection of LGE by CMR has excellent prognostic characteristics and may help guide risk stratification and management in NICM patients.
    Circulation Cardiovascular Imaging 12/2013; 7(2). DOI:10.1161/CIRCIMAGING.113.001144 · 5.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Several advances in molecular genetics and cardiac imaging of patients with hypertrophic cardiomyopathy (HCM) have been developed in recent years. The commercially available genetic testing is currently used (a) to identify affected relatives in families known to have HCM and (b) to differentiate HCM from metabolic storage disorders and other HCM phenocopies. Cardiovascular magnetic resonance has emerged as a useful tool to assess the magnitude and distribution of hypertrophy or mitral valve apparatus anatomy, which may have an impact on decision making regarding invasive management of HCM.
    F1000 Prime Reports 02/2014; 6:12. DOI:10.12703/P6-12
Show more


14 Reads
Available from